In a major step forward in fighting cervical cancer in China, a human papillomavirus (HPV) vaccine developed by Chinese researchers will be widely available for women under the age of 45. Starting in May 2020, the first batch of the Cecolin HPV vaccine will be available in community hospitals in provincial-level regions, including Hubei, Jilin, and Xinjiang Uygur Autonomous Region reported Xinhuanet on April 26, 2020. The Cecolin vaccine was jointly developed by Xiamen University and a subsidiary of YangShengTang Group in east China's Fujian Province, after an 18-year study. It was approved by the National Medical Products Administration in December 2019. The newly available vaccine can protect people against HPV 16 and 18, two major HPV types causing 70 percent of all cervical cancers, the third most common cancer among women. The World Health Organization (WHO) and many other countries recommend people to get vaccinated between the ages of 9 through 14. British pharmaceutic...